Lung function in Birt-Hogg-Dubé syndrome: a retrospective analysis of 96 patients.


Journal

Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602

Informations de publication

Date de publication:
24 05 2020
Historique:
received: 03 12 2019
accepted: 06 05 2020
entrez: 26 5 2020
pubmed: 26 5 2020
medline: 22 6 2021
Statut: epublish

Résumé

Birt-Hogg-Dubé syndrome (BHD) is a rare autosomal dominant disorder caused by mutations in the FLCN gene coding for folliculin. Its clinical expression includes cutaneous fibrofolliculomas, renal tumors, multiple pulmonary cysts, and recurrent spontaneous pneumothoraces. Data on lung function in BHD are scarce and it is not known whether lung function declines over time. We retrospectively assessed lung function at baseline and during follow-up in 96 patients with BHD. Ninety-five percent of BHD patients had multiple pulmonary cysts on computed tomography and 59% had experienced at least one pneumothorax. Mean values of forced expiratory volume in 1 second (FEV Cystic lung disease in BHD does not affect respiratory function at baseline except for slightly increased RV and reduced DLco. No significant deterioration of lung function occurs in BHD over a follow-up period of 6 years.

Sections du résumé

BACKGROUND
Birt-Hogg-Dubé syndrome (BHD) is a rare autosomal dominant disorder caused by mutations in the FLCN gene coding for folliculin. Its clinical expression includes cutaneous fibrofolliculomas, renal tumors, multiple pulmonary cysts, and recurrent spontaneous pneumothoraces. Data on lung function in BHD are scarce and it is not known whether lung function declines over time. We retrospectively assessed lung function at baseline and during follow-up in 96 patients with BHD.
RESULTS
Ninety-five percent of BHD patients had multiple pulmonary cysts on computed tomography and 59% had experienced at least one pneumothorax. Mean values of forced expiratory volume in 1 second (FEV
CONCLUSIONS
Cystic lung disease in BHD does not affect respiratory function at baseline except for slightly increased RV and reduced DLco. No significant deterioration of lung function occurs in BHD over a follow-up period of 6 years.

Identifiants

pubmed: 32448321
doi: 10.1186/s13023-020-01402-y
pii: 10.1186/s13023-020-01402-y
pmc: PMC7245949
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

120

Références

Ann Am Thorac Soc. 2017 May;14(5):706-713
pubmed: 28248571
Lancet Oncol. 2009 Dec;10(12):1199-206
pubmed: 19959076
Respir Med. 2004 Jun;98(6):536-41
pubmed: 15191039
Eur Respir J. 2005 Nov;26(5):948-68
pubmed: 16264058
Eur Respir J. 2005 Oct;26(4):720-35
pubmed: 16204605
Chest. 2007 Aug;132(2):679-84
pubmed: 17505035
PLoS One. 2017 Dec 8;12(12):e0188771
pubmed: 29220357
Eur Respir J. 2019 Apr 4;53(4):
pubmed: 30846465
Proc Natl Acad Sci U S A. 2013 Sep 10;110(37):14960-5
pubmed: 23983265
Lung. 2014 Dec;192(6):967-74
pubmed: 25201087
Respir Res. 2016 Feb 29;17:22
pubmed: 26928018
Am J Hum Genet. 2005 Jun;76(6):1023-33
pubmed: 15852235
Chest. 1996 Jan;109(1):131-7
pubmed: 8549175
Medicine (Baltimore). 1999 Sep;78(5):321-37
pubmed: 10499073
Eur Respir J. 2005 Sep;26(3):511-22
pubmed: 16135736
Thorax. 2000 Dec;55(12):1052-7
pubmed: 11083892
Proc Natl Acad Sci U S A. 2006 Oct 17;103(42):15552-7
pubmed: 17028174
Cancer Cell. 2002 Aug;2(2):157-64
pubmed: 12204536
Korean J Intern Med. 2019 Jul;34(4):830-840
pubmed: 30360018
Eur J Radiol. 2012 Jun;81(6):1340-6
pubmed: 21550193
Am J Respir Crit Care Med. 2007 May 15;175(10):1044-53
pubmed: 17322109
Eur J Radiol. 2011 Mar;77(3):403-9
pubmed: 19782489
Fam Cancer. 2013 Sep;12(3):387-96
pubmed: 23715758
AJR Am J Roentgenol. 2011 Feb;196(2):349-52
pubmed: 21257886
Ann Am Thorac Soc. 2016 Mar;13(3):342-9
pubmed: 26799509
Arch Dermatol. 1977 Dec;113(12):1674-7
pubmed: 596896
Eur Respir J. 2005 Aug;26(2):319-38
pubmed: 16055882
Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):393-400
pubmed: 11927500
Eur Respir J. 2010 Jan;35(1):14-26
pubmed: 20044458
Oncogene. 2009 Apr 2;28(13):1594-604
pubmed: 19234517
Am J Respir Crit Care Med. 2006 Jan 1;173(1):105-11
pubmed: 16210669
Respir Med. 2011 May;105(5):768-74
pubmed: 21356586
Eur Respir J. 1993 Mar;6 Suppl 16:5-40
pubmed: 24576915

Auteurs

C Daccord (C)

Service de pneumologie, Centre hospitalier universitaire vaudois, Université de Lausanne, Rue du Bugnon 46, CH-1011, Lausanne, Switzerland.

V Cottin (V)

Service de pneumologie, Centre national coordinateur de référence des maladies pulmonaires rares, hôpital Louis Pradel, Hospices Civils de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, UMR754 INRA, IVPC, Lyon, France.

G Prévot (G)

Service de pneumologie, Centre hospitalier universitaire de Toulouse, Toulouse, France.

Y Uzunhan (Y)

Service de pneumologie, Assistance Publique Hôpitaux de Paris, Hôpital Avicenne, INSERM UMR 1272, Université Paris 13, Bobigny, France.

J F Mornex (JF)

Service de pneumologie, Centre national coordinateur de référence des maladies pulmonaires rares, hôpital Louis Pradel, Hospices Civils de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, UMR754 INRA, IVPC, Lyon, France.

P Bonniaud (P)

Service de Pneumologie et Soins Intensifs Respiratoires, Centre hospitalier universitaire Dijon/Bourgogne, Université Bourgogne-Franche Comté, INSERM U123-1, Dijon, France.

R Borie (R)

Service de pneumologie, Assistance Publique Hôpitaux de Paris, Hôpital Bichat - Claude Bernard, Paris, France.

A Briault (A)

Service de pneumologie, Centre hospitalier universitaire de Grenoble, Grenoble, France.

M A Collonge-Rame (MA)

Service de génétique biologique - histologie, UF cytogénétique, UF consultations d'oncogénétique, Centre hospitalier universitaire de Besançon, Besançon, France.

B Crestani (B)

Service de pneumologie, Assistance Publique Hôpitaux de Paris, Hôpital Bichat - Claude Bernard, Paris, France.

G Devouassoux (G)

Service de pneumologie, Hospices Civils de Lyon, Hôpital de la Croix-Rousse, Lyon, France.

O Freynet (O)

Service de pneumologie, Assistance Publique Hôpitaux de Paris, Hôpital Avicenne, INSERM UMR 1272, Université Paris 13, Bobigny, France.

A Gondouin (A)

Service de pneumologie, Centre hospitalier universitaire de Besançon, Besançon, France.

P A Hauss (PA)

Centre hospitalier intercommunal Elbeuf - Louviers - Val de Reuil, Elbeuf, France.

C Khouatra (C)

Service de pneumologie, Centre national coordinateur de référence des maladies pulmonaires rares, hôpital Louis Pradel, Hospices Civils de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, UMR754 INRA, IVPC, Lyon, France.

S Leroy (S)

Service de pneumologie, Université Côte d'Azur, Centre hospitalier universitaire de Nice, CNRS, INSERM, FHU OncoAge, Nice, France.

S Marchand-Adam (S)

Service de pneumologie, Centre hospitalier universitaire de Tours, Tours, France.

C Marquette (C)

Service de pneumologie, Université Côte d'Azur, Centre hospitalier universitaire de Nice, CNRS, INSERM, FHU OncoAge, Nice, France.

D Montani (D)

Service de Pneumologie, Université Paris-Sud, Assistance Publique Hôpitaux de Paris, INSERM UMR S999, Hôpital de Bicêtre, Le Kremlin Bicêtre, France.

J M Naccache (JM)

Service de Pneumologie, Site constitutif du Centre de référence des maladies pulmonaires rares OrphaLung, Assistance Publique Hôpitaux de Paris, Hôpital Tenon, Paris, France.

G Nadeau (G)

Centre hospitalier Métropole Savoie, UF de Génétique chromosomique, Chambéry, France.

N Poulalhon (N)

Service de dermatologie, Hospices Civils de Lyon, Centre hospitalier Lyon-Sud, Lyon, France.

M Reynaud-Gaubert (M)

Service de pneumologie, Centre de compétences des maladies pulmonaires rares, Assistance Publique Hôpitaux de Marseille, Centre hospitalier universitaire de Marseille, Aix Marseille Université, Marseille, France.

M Salaun (M)

Service de pneumologie, Centre hospitalier universitaire de Rouen, Rouen, France.

B Wallaert (B)

Service de pneumologie, Centre hospitalier universitaire de Lille, Lille, France.

J F Cordier (JF)

Service de pneumologie, Centre national coordinateur de référence des maladies pulmonaires rares, hôpital Louis Pradel, Hospices Civils de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, UMR754 INRA, IVPC, Lyon, France.

M Faouzi (M)

Division de biostatistique, Centre universitaire de médecine générale et santé publique (Unisanté), Université de Lausanne, Lausanne, Switzerland.

R Lazor (R)

Service de pneumologie, Centre hospitalier universitaire vaudois, Université de Lausanne, Rue du Bugnon 46, CH-1011, Lausanne, Switzerland. romain.lazor@chuv.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH